Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s Vimpat Gets FDA Approval For Epileptic Seizures

This article was originally published in The Pink Sheet Daily

Executive Summary

Belgian specialty pharma hopes to launch drug in U.S. early next year; says blockbuster sales could follow.

You may also be interested in...



China's Epilepsy Market Growing Rapidly; Attracting More Multinational Companies

SHANGHAI - The Chinese anti-epilepsy drug market is expected to grow at an annual rate of roughly 30 percent in coming years, and multinational companies account for most of that market share, healthcare analysts predict

FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality

FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning

FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality

FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel